More than half of participants in the GRADE trial had ECG abnormalities (57.1%) and ECG-defined cardiovascular autonomic neuropathy (52.8%) at baseline. The presence of these abnormalities was ...
Collaboration brings the next generation of cutting-edge ECG technology to trial participants' homes, enabling accurate cardiac safety trial measurements with fewer site visits. Clario and AliveCor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback